Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Autolus Limited
Seagen Inc.
Mayo Clinic
Corvus Pharmaceuticals, Inc.
Fondazione Italiana Linfomi - ETS
Hoffmann-La Roche
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Seagen Inc.
Medical College of Wisconsin
Mayo Clinic
Fudan University
Novartis
Princess Maxima Center for Pediatric Oncology
Turning Point Therapeutics, Inc.
City of Hope Medical Center
Baylor College of Medicine
UNC Lineberger Comprehensive Cancer Center
New York Medical College
Mayo Clinic
M.D. Anderson Cancer Center
Takeda
Pfizer
Universität des Saarlandes
Memorial Sloan Kettering Cancer Center
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
City of Hope Medical Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Washington University School of Medicine
Children's Cancer Group, China
Ohio State University Comprehensive Cancer Center
Boehringer Ingelheim
Eastern Cooperative Oncology Group
BeiGene
Children's Oncology Group
Takeda
Ruijin Hospital
Takeda
Stanford University
Children's Oncology Group
University of Nebraska
European Organisation for Research and Treatment of Cancer - EORTC